RESUMO
Canine separation anxiety is a common behavioral problem presented to veterinarians. Associated behaviors are distressing to both dog and owner, have the potential to disrupt the human-companion animal bond, and may lead to euthanasia. The results of this study demonstrate the clinical efficacy and safety of Reconcile (fluoxetine, 1 to 2 mg/kg/day [0.45 to 0.91 mg/lb/day]), in conjunction with behavior management, for the treatment of canine separation anxiety. The beef flavored chewable formulation was palatable to treated dogs and easy to administer. This study provides to veterinarians and owners valuable information about an effective separation anxiety treatment plan that combines use of Reconcile with behavior modification.
Assuntos
Antidepressivos de Segunda Geração/administração & dosagem , Ansiedade de Separação/tratamento farmacológico , Comportamento Animal , Doenças do Cão/tratamento farmacológico , Fluoxetina/administração & dosagem , Inibidores Seletivos de Recaptação de Serotonina/administração & dosagem , Administração Oral , Animais , Ansiedade de Separação/psicologia , Canadá , Doenças do Cão/psicologia , Cães , Método Duplo-Cego , Vínculo Humano-Animal , Humanos , Resultado do Tratamento , Estados UnidosRESUMO
As our knowledge expands, behavioral pharmacology plays an increasingly important role in behavioral medicine. Drugs traditionally categorized as anxiolytics, antidepressants, anticonvulsants, and hormones may be used to help manage a range of animal behavioral problems. Knowledge of how these agents act in the body and interact with other agents is imperative for safe and efficacious use.